← Leaderboards
Frederick Oliver Cope
Navidea Biopharmaceuticals, Inc.
$8,156,978
Attributed
$8,156,978
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.7M · FY2012–17$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$8,156,978 · 8
By mechanism
R44$7,835,140 · 7
R43$321,838 · 1
Top collaborators
No co-investigators on record.
Most similar at Navidea Biopharmaceuticals, Inc.
Same institution · by research overlap
- David Allen Ralph$2,331,001
- Michael Blue$750,000
Others in their field
Top investigators on “Small Business Innovation Research Grant”
- David Heimbrook · Leidos Biomedical Research, Inc.$122,677,088
- Praduman Jain · Vignet, Inc.$106,968,877
- Stephen Lev Hoffman · Sanaria, Inc.$37,771,680
- Eric Baer · Case Western Reserve University$37,136,000
- John B Buse · University Of North Carolina Chapel Hill$23,865,764
- Gary Fanger · Rise Therapeutics, Llc$23,463,293
Research focus
Small Business Innovation Research GrantClinical ResearchSafetyInstitutional Review BoardsDiagnosticBiological ProductsGrantLymph NodesBaseTumorDesignQuality Of CareAnimalsPre-ClinicalSiteTrainingAffinitySpecificityRadiopharmaceuticalsPreclinical StudyMannose ReceptorImageEvaluationFda Approved
Grant awards (16)
CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages$939,552
R44 · FY2017 · CA · contact PI
99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages$374,335
R44 · FY2017 · AR · contact PI
99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages$1,125,665
R44 · FY2016 · AR · contact PI
CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv$688,135
R44 · FY2016 · CA · contact PI
Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept$633,492
R44 · FY2016 · CA · contact PI
CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages$232,464
R44 · FY2016 · CA · contact PI
CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv$538,135
R44 · FY2015 · CA · contact PI
99mTc-Tilmanocept Targeting of Cardiovascular Plaque in HIV Subjects$321,838
R43 · FY2015 · HL · contact PI
Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept$300,000
R44 · FY2015 · CA · contact PI
99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages$224,993
R44 · FY2015 · AR · contact PI
[18F]NAV4694 Imaging to Identify MCI Patients at Risk for Alzheimer's Dementia$1,257,437
R44 · FY2014 · AG · contact PI
Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology$629,160
R44 · FY2014 · AG · contact PI
99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries$165,917
R44 · FY2014 · CA · contact PI
Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology$258,824
R44 · FY2013 · AG · contact PI
[18F]NAV4694 Imaging to Identify MCI Patients at Risk for Alzheimer's Dementia$151,814
R44 · FY2013 · AG · contact PI
CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv$315,217
R44 · FY2012 · CA · contact PI